retatrutide triple agonist obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Triple hormone receptor agonist retatrutide

If youve tried multiple approaches without lasting success, youre part of a much larger picture

However, as with injectable GLP-1s, cost may be a consideration in determining access to the Wegovy pill, particularly since many insurance plans dont cover obesity medications, Dushay says

This works well for researchers who have reached higher maintenance doses or who prefer smaller injection volumes

Your Core Message: A medically supervised, affordable, results-driven weight loss program delivered 100% virtually

Kwaliteit & Certificering

For example, if you inject into the left side of your abdomen one week, move to the right side or your thigh the following week